alx-5407 and Schizophrenia

alx-5407 has been researched along with Schizophrenia* in 1 studies

Other Studies

1 other study(ies) available for alx-5407 and Schizophrenia

Article	Year
The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. Bioorganic & medicinal chemistry letters, 2004, Aug-02, Volume: 14, Issue:15 Elevation of glycine levels and activation of the NMDA receptor by inhibition of the glycine transporter 1 (GlyT-1) is a potential strategy for the treatment of schizophrenia. A novel series of GlyT-1 inhibitors have been identified containing the 2-arylsulfanyl-phenylpiperazine motif. The most prominent member of this series, (R)-4-[5-chloro-2-(4-methoxy-phenylsulfanyl)-phenyl]-2-methyl-piperazin-1-yl-acetic acid (31) is a potent glycine transporter-1 inhibitor (IC(50)=150 nM), which elevated glycine levels in rat ventral hippocampus as measured by microdialysis in vivo at doses of 1.2-4.6 mg/kg s.c. Topics: Acetates; Amino Acid Transport Systems, Neutral; Animals; Antipsychotic Agents; Glycine; Glycine Plasma Membrane Transport Proteins; Hippocampus; Humans; Kinetics; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Rats; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Structure-Activity Relationship	2004

Article

Year

The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors.

Bioorganic & medicinal chemistry letters, 2004, Aug-02, Volume: 14, Issue:15

Elevation of glycine levels and activation of the NMDA receptor by inhibition of the glycine transporter 1 (GlyT-1) is a potential strategy for the treatment of schizophrenia. A novel series of GlyT-1 inhibitors have been identified containing the 2-arylsulfanyl-phenylpiperazine motif. The most prominent member of this series, (R)-4-[5-chloro-2-(4-methoxy-phenylsulfanyl)-phenyl]-2-methyl-piperazin-1-yl-acetic acid (31) is a potent glycine transporter-1 inhibitor (IC(50)=150 nM), which elevated glycine levels in rat ventral hippocampus as measured by microdialysis in vivo at doses of 1.2-4.6 mg/kg s.c.

Topics: Acetates; Amino Acid Transport Systems, Neutral; Animals; Antipsychotic Agents; Glycine; Glycine Plasma Membrane Transport Proteins; Hippocampus; Humans; Kinetics; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Rats; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Structure-Activity Relationship

2004